<DOC>
	<DOC>NCT02212080</DOC>
	<brief_summary>This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1214784 using a placebo controlled, randomized, single center design. In addition the bioavailability of two different liquid formulations will be compared.</brief_summary>
	<brief_title>First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784</brief_title>
	<detailed_description />
	<criteria>Healthy female subjects Age 45 to 65 years Body mass index (BMI) above/equal 20 and below/equal 30 kg/m2 Postmenopausal state Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Known or suspected malignant or benign tumors Known or suspected liver disorders, relevant kidney diseases, known cardiovascular diseases, known metabolic disorders Regular use of medicines</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>